Treatment of hyperlactacidemia in cirrhotic patients with pyridoxine-alpha-ketoglutarate (PAK).
After pyridoxine-alpha-ketoglutarate (PAK) was administered to patients with hepatic cirrhosis, the blood level values for lactic acid and ammonia showed a statistically significant reduction. These results suggest that PAK can be used for treatment adn prevention of hyperlactacidemia secondary to chronic hepatopathy.